A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia

Clinical Neuropharmacology

Volumn 33, Issue 6, 2010, Pages 288-292

  Venkatasubramanian, Ganesan ^a   Chittiprol, Seetharamaiah ^a,b   Neelakantachar, Narendran ^a   Shetty, Taranath K ^a   Gangadhar, Bangalore N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

antipsychotic; leptin; schizophrenia; weight gain

Indexed keywords

FLUPENTIXOL; LEPTIN; OLANZAPINE; RISPERIDONE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOMS; SCALE FOR ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; LEPTIN; LONGITUDINAL STUDIES; MALE; MATCHED-PAIR ANALYSIS; MOTOR ACTIVITY; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 78650295807     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181fa2a6f     Document Type: Article

References (35)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209- 1223.
2. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1):20-27.
3. Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005;5:3.
4. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008;13(10):918-929.
5. Singh MM, De Dios LV, Kline NS. Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 1970;11(6):562-570.
6. Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153(6):817-819.
7. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149(1):68-72.
8. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003;59(1):19-27.
9. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22(3):244-251.
10. Gupta S, Droney T, Al-Samarrai S, et al. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999;19(3):273-275.
11. Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003;64(3):316-320.
12. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62(4):231-238.
13. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62(Suppl 2):41-44.
14. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156(2):312-314.
15. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiologyVemerging clinical applications. Nat Clin Pract Endocrinol Metab 2006;2(6):318-327.
16. Sentissi O, Epelbaum J, Olie JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008;34(6):1189-1199.
17. Harvey J, Solovyova N, Irving A. Leptin and its role in hippocampal synaptic plasticity. Prog Lipid Res 2006;45(5):369-378.
18. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004;174(1):151-162.
19. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33;quiz 34-57.
20. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
21. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA.: University of Iowa; 1983
22. Mohan V, Deepa R, Deepa M, et al. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. J Assoc Physicians India 2005;53:759-763.
23. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164(10):1557-1560.
24. Wang HC, Yang YK, Chen PS, et al. Increased plasma leptin in antipsychotic-naive females with schizophrenia, but not in males. Neuropsychobiology 2007;56(4):213-215.
25. Tang BL. Leptin as a neuroprotective agent. Biochem Biophys Res Commun 2008;368(2):181-185.
26. Schwartz MW, Peskind E, Raskind M, et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996;2(5):589-593.
27. Burguera B, Couce ME, Long J, et al. The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. Neuroendocrinology 2000;71(3):187-195.
28. Baicy K, London ED, Monterosso J, et al. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc Natl Acad Sci USA 2007;104(46):18276-18279.
29. Matochik JA, London ED, Yildiz BO, et al. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J Clin Endocrinol Metab 2005;90(5):2851-2854.
30. Narita K, Kosaka H, Okazawa H, et al. Relationship between plasma leptin level and brain structure in elderly: a voxel-based morphometric study. Biol Psychiatry 2008.
31. Shenton ME, Dickey CC, Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res 2001;49(1-2):1-52.
32. Kirkpatrick B, Messias E, Harvey PD, et al. Is schizophrenia a syndrome of accelerated aging? Schizophr Bull 2008;34(6):1024-1032.
33. Jaquet D, Gaboriau A, Czernichow P, et al. Relatively low serum leptin levels in adults born with intra-uterine growth retardation. Int J Obes Relat Metab Disord 2001;25(4):491-495.
34. Figlewicz DP, Evans SB, Murphy J, et al. Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 2003;964(1):107-115.
35. Waltz JA, Schweitzer JB, Gold JM, et al. Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology 2008.